通用名称

pomalidomide

儿科标签批准日期

2020/11/20 0:00:00

特定指示/秒

Progressive or refractory CNS tumors

标签更改摘要

- Safety and effectiveness have not been established in pediatric patients. - Safety and effectiveness were assessed but not established in two open-label studies: a dose escalation study in 25 pediatric patients aged 5 to < 17 years old was within the range observed in adult patients with MM but higher than the exposure observed in adult patients with KS. - Information on PK parameters.

治疗类别

Melanoma

立法类型

BPCA Only

产品说明书链接